Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 5/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13073944 | 0.82 | UHRF1 (0.42) | PDE3BPDE3AMEN1KMT2AGRM2 | |
| SCHEMBL13073831 | 0.79 | PGK1 (0.42) | PDE3BPDE3AMEN1KMT2AGRM2 | |
| SCHEMBL14268085 | 0.78 | TUBB1 (0.41) | UHRF1CYP1A2CYP2A6 | |
| SCHEMBL14392734 | 0.77 | EPHX2 (0.37) | PDE2AEPHX2ALOX5APFEN1 | |
| SCHEMBL13073948 | 0.77 | PDE2A (0.38) | PDE2AEPHX2ALOX5APFEN1KCNN4 | |
| SCHEMBL17979085 | 0.72 | PDE3B (0.37) | PDE3BPDE3ANTRK1 | |
| SCHEMBL12828161 | 0.69 | CYP11B2 (0.39) | UHRF1CYP1A2CYP2A6 | |
| SCHEMBL25669006 | 0.69 | — | — | |
| SCHEMBL900955 | 0.68 | PDE2A (0.50) | PDE2AEPHX2GRM2 | |
| SCHEMBL23044965 | 0.68 | SCN5A (0.37) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805158-B1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS INC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-7915253-B2 | 4-[2,6-Dimethyl-4-(4-trifluoromethoxy-phenyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid; peroxisome proliferator activated receptors modulator; antidiabetic, antiinflammatory agent; obesity, hyperinsulinemia, metabolic syndrome X, polycystic ovary syndrome, ischemia-associated organ injury | KALYPSYS, INC (US) | 2011-03-29 | — | — | US | disclosed |
| US-7834004-B2 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | KALYPSYS, INC (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090264417-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090029971-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029971-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | PPARG, PPARA, PPARD | PDE2A 933/4885EPHX2 3006/4885PDE3B 993/4885 |
| US-20090264417-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | PPARG, PPARA, PPARD | PDE2A 933/4885EPHX2 3006/4885PDE3B 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.